Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
NCT ID | NCT02162888 |
Title | A Phase I, Bioequivalence Study to Evaluate Two Formulations of Bendamustine (BDM) Hydrochloride (HCl) Administered to Cancer Patients |
Recruitment | Completed |
Gender | both |
Phase | Phase I |
Variant Requirements | No |
Sponsors | Eagle Pharmaceuticals, Inc. |
Indications | |
Therapies | |
Age Groups: | adult |
Covered Countries | USA |
Facility | Status | City | State | Zip | Country | Details |
---|---|---|---|---|---|---|
Oncology Institute of Hope and Innovation | Long Beach | California | United States | Details | ||
Cancer Center of Kansas | Wichita | Kansas | United States | Details | ||
Regional Cancer Care Associates | Cherry Hill | New Jersey | United States | Details | ||
Penn State University Hershey Medical Center | Hershey | Pennsylvania | United States | Details | ||
Greenville Hospital System University Medical Center | Greenville | South Carolina | United States | Details | ||
Texas Oncology | Fort Worth | Texas | United States | Details | ||
Scott & White Healthcare | Temple | Texas | United States | Details | ||
Virginia Oncology Associates | Norfolk | Virginia | United States | Details | ||
Evergreen Hematology & Oncology | Spokane | Washington | United States | Details | ||
Yakima Valley Memorial Hospital/North Star Lodge | Yakima | Washington | United States | Details |